Core Insights - Boston Scientific reported Q4 2025 revenue of $5.286 billion, a 15.9% year-over-year increase, exceeding market expectations of $5.280 billion [27][32] - The electrophysiology segment, which was highly anticipated, generated $890 million in sales, falling short of the market expectation of $933 million, leading to a stock price drop of over 17% [28][19] - The company's overall performance was strong, but the market reacted negatively due to concerns over the sustainability of growth driven by a single segment [19][48] Financial Performance - Q4 2025 revenue: $5.286 billion, up 15.9% YoY [32] - GAAP net profit: $672 million, up 18.7%, with earnings per share of $0.45 [32] - Adjusted EPS: $0.80, exceeding the company's guidance of $0.77-$0.79 [32] - Full-year revenue surpassed $20 billion for the first time, with a 19.9% YoY increase [33] Segment Performance - Cardiovascular segment revenue: $3.477 billion, up 18.2%, the strongest performing segment [32] - Electrophysiology segment growth was 35% in Q4, but analysts expressed concerns over the sustainability of this growth [44][39] - The Watchman device, another flagship product, reported $535 million in revenue, missing expectations by $4 million, indicating potential market saturation [45][44] Market Dynamics - The electrophysiology segment is critical to Boston Scientific's growth narrative, with the PFA technology previously showing explosive growth [37][39] - Competition is intensifying with the entry of Medtronic's PulseSelect and Johnson & Johnson's Varipulse, which may erode Boston Scientific's market share [41][43] - The U.S. market for PFA technology is experiencing a transition phase, which may limit future growth as initial conversions to PFA have been completed [39] Future Outlook - The company anticipates organic revenue growth of 10-11% for 2026, a significant slowdown from 15.8% in 2025 [49][48] - Management remains confident in maintaining market leadership in electrophysiology, with plans for product innovation and expansion into new indications [54] - International markets, particularly in China and Japan, present significant growth opportunities as they are still in early stages of PFA technology adoption [54]

Group 1 - The eighth China International Import Expo (CIIE) is set to take place from November 5 to 10 in Shanghai, with the theme "New Era, Shared Future" [1] - The expo will feature six major exhibition areas, including an upgraded "Automobile and Smart Mobility Exhibition Area" and a focus on global top medical technology achievements in the medical exhibition area [2] - A special area for least developed countries' products will be established for the first time, promoting the use of "zero tariff" policies for enterprises from these nations [2] Group 2 - New initiatives for enhancing supply-demand matching efficiency include tailored strategies for groups, an online registration system for group visits, and a comprehensive online supply-demand platform [3] - The exhibition will optimize digital services and reduce some service fees to enhance the overall experience for exhibitors [3] Group 3 - Over 50 countries and international organizations have confirmed participation, with Sweden and the UAE serving as guest countries, and Kyrgyzstan making its debut at the expo [4] - A record number of enterprises from Canada, Malaysia, and New Zealand will participate, with new provincial and municipal representations from Saskatchewan and Almaty [4] Group 4 - Boston Scientific will showcase several innovative products, including the Intera 3000 liver perfusion pump and the FARAPULSE ablation system, emphasizing the importance of the expo for deepening cooperation in China [5] - Sanofi will highlight its innovative drugs, including Dupixent and the first RSV prevention drug for infants, showcasing the expo as a platform for accelerating innovation [5] Group 5 - The expo aims to strengthen the three key characteristics of "innovation-driven, consumption upgrade, and inclusive development," contributing to global economic recovery through international procurement and investment promotion [6]

近日，思宇MedTech注意到波士顿科学的一则招聘信息：房颤解决方案事业部启动"百岗校招"计划， 面向2025届应届生及毕业两年内的候选人，开放150 个临床技术培训生岗位，覆盖全国34个省市。 与以往偏向市场、销售类岗位的招聘不同，此次的重点落在了被业内称为"跟台岗"的 临床一线技术支持人员 。根据招聘描述，新入职者将直接参与房颤治 疗手术全过程，包括术前准备、术中支持及术后沟通。换句话说，他们从培训结束后就能站上手术现场，服务于真实病例和真实操作。 这看上去不仅是一轮简单的人才扩充，更是波士顿科学在中国房颤市场加速深化临床部署、全面提升一线渗透力的重要举措。 2024年，波士顿科学的 FARAPULSE脉冲电场消融系统 获得国家药品监督管理局（NMPA）批准，成为国内首款进口PFA系统。同时，其在房颤卒中预防 方向上的代表产品—— Watchman左心耳封堵系统 ——也在中国进入成熟应用期。 在思宇看来，这场校招，是波士顿科学"重投临床、深耕一线"战略思路的具体体现。通过年轻技术人才的广泛铺设，波士顿科学或将打通产品—术式—医院 —医生之间的落地通路，为房颤整体解决方案在中国的本地化放量奠定基础。 一、房 ...

Core Viewpoint - Boston Scientific is accelerating its clinical deployment in the atrial fibrillation (AF) market in China by launching a recruitment plan for clinical technical trainees, indicating a strategic focus on enhancing frontline penetration and support [1][23]. Group 1: Market Observation of Atrial Fibrillation Treatment - Atrial fibrillation (AF) is the most common type of persistent arrhythmia, significantly increasing the risk of stroke and heart failure, with over 12 million patients in China [2]. - Catheter ablation is recognized as the most effective rhythm control method when drug therapy is inadequate, evolving from radiofrequency to cryoablation, and now to pulsed field ablation (PFA) technology [2][3]. - PFA technology offers high-targeted non-thermal ablation, minimizing damage to adjacent structures, and Boston Scientific's FARAPULSE is the first commercially available PFA system [2][3]. Group 2: FARAPULSE System Analysis - The FARAPULSE system is specifically designed for PFA, featuring a closed-loop optimization from energy mechanism to catheter design [4][7]. - It includes a unique catheter structure that enhances electrical field coverage and stability during procedures, with adjustable voltage parameters to ensure effective energy release while minimizing side effects [7][8]. - FARAPULSE is the first commercial catheter system designed from the ground up for PFA, ensuring rapid acceptance and replication by physicians globally [8][9]. Group 3: Global Validation and Innovation - FARAPULSE has the most extensive clinical research support and real-world validation among PFA systems, with over 250,000 patients treated globally by February 2025 [12][10]. - The system is evolving into a platform-type ablation system, enhancing adaptability across different hospital levels and operator skills [14]. - Boston Scientific is advancing its system capabilities towards visualization and platform integration, aiming for broader application in various arrhythmias [13][14]. Group 4: Local Advancement Strategy - FARAPULSE received rapid NMPA registration in China, officially launching in 2024 for treating drug-resistant, recurrent, symptomatic paroxysmal AF [15]. - The company is implementing a comprehensive strategy that includes technical deployment, training, and talent recruitment to build a foundational ecosystem for AF treatment in China [15][23]. - The recruitment of 150 clinical technical support positions across 34 provinces reflects Boston Scientific's commitment to local market development and talent cultivation [1][23]. Group 5: Comprehensive Solution for Atrial Fibrillation - Boston Scientific's FARAPULSE and Watchman systems together form a comprehensive treatment solution for AF, addressing both rhythm control and stroke prevention [19][20]. - The combination of these technologies represents a dual pillar model in AF management, enhancing clinical treatment efficiency and patient outcomes [20][21]. - The integration of these systems is expected to create a synergistic effect, optimizing operational efficiency and patient compliance in clinical settings [26].